Spectral MD Announces U.S. Burn AI Clinical Training Study Enrollment Completion
Successful completion of clinical study enrollment paves way for next phase of BARDA funding. Data used to finalize DeepView AI®-Burn algorithm. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary artificial intelligence...
Spectral MD Initiates EU Diabetic Foot Ulcer Clinical Study in Ireland
Data from the study to support regulatory submissions on track for 2023. Participation from distinguished EU principal investigators provides significant endorsement for DeepView™. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary...
Spectral MD Announces Positive Interim Results From DFU Clinical Study & Burn Clinical Study Update
DeepView® accuracy increases to 86% in diagnosis of DFU healing potential on day one Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with...